Stroke: Effect of implementing an evaluation and treatment protocol compliant with NINDS recommendations

Radiology

Volumn 228, Issue 3, 2003, Pages 659-668

  Stahl, James E ^a   Furie, Karen L ^a   Gleason, Suzanne ^b   Gazelle, G Scott ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TRINITY COLLEGE   (United States)

Author keywords

Brain, infarction; Cost effectiveness; Economics, medical; Radiology and radiologists, socioeconomic issues; Tissue plasminogen activator (TPA)

Indexed keywords

FIBRINOLYTIC AGENT; MANNITOL; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; HEALTH CARE DELIVERY; HUMAN; MEDICAL LITERATURE; MEDICAL SOCIETY; PHYSICIAN; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; STROKE;

CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; EMERGENCIES; HUMANS; MODELS, THEORETICAL; NATIONAL INSTITUTES OF HEALTH (U.S.); TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UNITED STATES;

EID: 0042431628     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2283021557     Document Type: Article

References (83)

1. U.S. Department of Health and Human Services. Current estimates from the National Health Interview Survey, 1995: vital and health statistics. Series 10: Data From the National Health Survey No. 199, 1998.
2. Rosamond W, Folsom A, Chambless L, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999; 30:736-743.
3. McCaig, LF, Burt CW. National Hospital Ambulatory Medical Care Survey: 1999 emergency department summary. Advance Data from Vital and Health Statistics No. 320. Hyattsville, Md: National Center for Health Statistics; 2001.
4. American Heart Association. 1999 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association, 1998.
5. Metropolitan Life Insurance Company. 1999 heart and stroke statistical update: statistical bulletin. New York, NY: Metropolitan Life Insurance Company, 1997.
6. Leibson C, Brown RD, Hass SL, O'Fallon WM, Whisnant JP. Utilization of acute care services in the year before and after first stroke: a population-based study. Neurology 1996; 46:861-869.
7. Rankin J. Cerebral vascular accidents in patients over 60. II. Prognosis. Scott Med J 1957; 2:200-215.
8. Thrombolytic therapy with streptokinase in acute ischemic stroke: the Multicenter Acute Stroke Trial-Europe Study Group. N Engl J Med 1996; 335:145-150.
9. Donnan G, Davis S, Chambers B, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996; 276:961-969.
10. Tissue plasminogen activator for acute stroke: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
11. Hacke W, Kaste M, Fieschi C. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017-1025.
12. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke: Multicentre Acute Stroke Trial - Italy (MAST-I) Group. Lancet 1995; 346:1509-1514.
13. Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training: NINDS TPA Stroke Study Group. Stroke 1994; 25:2220-2226.
14. Mahoney F, Barthel D. Functional evaluation: the Barthel Index. Md Med J 1965; 61-65.
15. Teasdale G, Knill-Jones R, van der Sande J. Observer variability in assessing impaired consciousness and coma. J Neurol Neurosurg Psychiatry 1978; 41:603-610.
16. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study - a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 1999; 282:2003-2011.
17. Rosamond W, Gorton R, Hinn A, Hohenhaus S, Morris D. Rapid response to stroke symptoms: the Delay in Accessing Stroke Healthcare (DASH) study. Ann Emerg Med 1998; 5:45-51.
18. Wester P, Radberg J, Lundgren B, Peltonen M. Factors associated with delayed admission to hospital and in-hospital delays in acute stroke and TIA: a prospective, multicenter study - Seek-Medical-Attention-in-Time Study Group. Stroke 1999; 30:40-48.
19. Williams J, Rosamond W, Morris D. Stroke symptom attribution and time to emergency department arrival: the delay in accessing stroke healthcare study. Acad Emerg Med 2000; 7:93-96.
20. Proceedings of a National Symposium on Rapid Identification and Treatment of Acute Stroke. Vol 2001. Bethesda, Md: National Institute of Neurological Disorders and Stroke, 1996.
21. Smith M, Doliszny K, Shahar E, McGovern P, Arnett D, Luepker R. Delayed hospital arrival for acute stroke: the Minnesota Stroke Survey. Ann Intern Med 1998; 129:190-196.
22. Morris D, Rosamond W, Hinn A, Gorton R. Time delays in accessing stroke care in the emergency department. Acad Emerg Med 1999; 6:218-223.
23. Lacy CR, Suh DC, Bueno M, Kostis JB. Delay in presentation and evaluation for acute stroke: Stroke Time Registry for Outcomes Knowledge and Epidemiology (S.T.R.O.K.E.). Stroke 2001; 32:63-69.
24. Azzimondi G, Bassein L, Fiorani L, et al. Variables associated with hospital arrival time after stroke. Stroke 1997; 28:537-542.
25. Fodelholm R, Murros K, Rissanen A, Ilmavirta M. Factors delaying hospital admission after acute stroke. Stroke 1996; 27: 398-400.
26. Kothari R, Jauch E, Broderick J, et al. Acute stroke: delays to presentation and emergency department evaluation. Ann Emerg Med 1999; 33:3-8.
27. Morris D, Rosamond W, Madden K, Schultz C, Hamilton S. Prehospital and emergency department delays after acute stroke: the Genentech Stroke Presentation Survey. Stroke 2000; 31:2585-2590.
28. Schroeder E, Rosamond W, Morris D, Evenson K, Hinn A. Determinants of use of emergency medical services in a population with stroke symptoms. Stroke 2000; 31:2591-2596.
29. Smith R, Scott P, Grant R, Chudnofsky C, Frederiksen S. Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: a retrospective analysis. Ann Emerg Med 1999; 6:618-625.
30. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352:1245-1251.
31. Streifler J, Davidovitch S, Sendovski U. Factors associated with the time of presentation of acute stroke patients in an Israeli community hospital. Neuroepidemiology 1998; 17:161-166.
32. Proceedings of a National Symposium on Rapid Identification and Treatment of Acute Stroke, National Institutes of Health, December 12-13, 1996. Bethesda, Md: National Institute of Neurological Disorders and Stroke.
33. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press, 1996; 425.
34. Banks J. Handbook of simulation. New York, NY: Wiley, 1998.
35. Law A, Kelton D. Simulation modeling and analysis. New York, NY: McGraw-Hill, 1991.
36. Gomez C, Malkoff M, Sauer C, Tulyapronchote R, Burch C, Banet G. Code stroke: an attempt to shorten inhospital therapeutic delays. Stroke 1994; 25:1920-1923.
37. Jorgensen H, Nakayama H, Raaschou H. The effect of a stroke unit: reductions in mortality, discharge rate to nursing home, length of hospital stay, and cost - a community-based study. Stroke 1995; 26:1178-1182.
38. Lanzieri C, Tarr R, Landis D, et al. Cost-effectiveness of emergency intraarterial intracerebral thrombolysis: a pilot study. AJNR Am J Neuroradiol 1995; 16:1987-1993.
39. Tilley B, Lyden P, Brott T, Lu M, Levine S, Welch K. Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Arch Neurol 1997; 54:1466-1474.
40. Wein T, Hickenbottom S, Alexandrov A. Thrombolysis, stroke units and other strategies for reducing acute stroke costs. Pharmacoeconomics 1998; 14:603-611.
41. Alberts M, Bertels C, Dawson D. An analysis of time of presentation after stroke. JAMA 1990; 263:65-68.
42. Davalos A, Castillo J, Martinez-Vila E. Delay in neurological attention and stroke outcome: Cerebrovascular Diseases Study Group of the Spanish Society of Neurology. Stroke 1995; 26:2233-2237.
43. O'Connor R, McGraw P, Edelsohn L. Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. Ann Emerg Med 1999; 33:9-14.
44. Adams HP Jr, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke - a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Stroke 1996; 27:1711-1718.
45. Mayberg M, Batjer H, Dacey R, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Circulation 1994; 90:2592-2605.
46. Schievink W. Intracranial aneurysms. N Engl J Med 1997; 336:28-40.
47. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1997. Hyattsville, Md: Vital and Health Statistics Series 13, No. 143. 1997; 13.
48. Table 26: number of deaths, death rates, and age-adjusted death rates for major causes of death for the United States, each division, each state, Puerto Rico, Virgin Islands, Guam, American Samoa, and Northern Marianas, 1998 -. Hyattsville, Md: National Vital Statistics Reports, Vol 48, No. 11, July 24, 2000, 1998.
49. Nussbaum ES, Heros RC, Erickson DL. Cost-effectiveness of carotid endarterectomy. Neurosurgery 1996; 37:237-244.
50. Sacco SE, Whisnant JP, Broderick JP, Phillips SJ, O'Fallon WM. Epidemiological characteristics of lacunar infarcts in a population. Stroke 1991; 22:1236-1241.
51. Sacco R, Wolf P, Kannel W, McNamara P. Survival and recurrence following stroke: the Framingham Study. Stroke 1982; 13: 290-295.
52. Alexander M. Stroke rehabilitation outcome: a potential use of predictive variables to establish levels of care. Stroke 1994; 25:128-134.
53. Falconer J, Naughton B, Strasser D, Sinacore J. Stroke inpatient rehabilitation: a comparison across age groups. J Am Geriatr Soc 1994; 42:39-44.
54. Granger C, Hamilton B, Fiedler R. Discharge outcome after stroke rehabilitation. Stroke 1992; 23:978-982.
55. Fagan S, Morgenstern L, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998; 50:883-890.
56. Mark D, Hlatky M, Califf R, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared to streptokinase for acute myocardial infarction. N Engl J Med 1995; 332:1418-1424.
57. Solomon N, Glick H, Russo C, Lee J, Schulman K. Patient preferences for stroke outcomes. Stroke 1994; 25:1721-1725.
58. Tengs TO, Yu M, Luistro E. Health-related quality of life after stroke: a comprehensive review. Stroke 2001; 32:964-972.
59. Gage B, Cardinalli A, Owens D. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996; 156:1829-1836.
60. Duncan P, Lai S, Keighley J. Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology 2000; 39:835-841.
61. Hallan S, Asberg A, Indredavik B, Wideroe T. Quality of life after cerebrovascular stroke: a systematic study of patients' preferences for different functional outcomes. J Intern Med 1999; 246:309-316.
62. Post P, Stiggelbout A, Wakker P. The utility of health states after stroke: a systematic review of the literature. Stroke 2001; 32:1425-1429.
63. Aoki N, Kitahara T, Fukui T, Beck J, Soma K, Yamamoto W. Management of unruptured intracranial aneurysm in Japan: a Markovian decision analysis with utility measurements based on the Glasgow coma scale. Med Decis Making 1998; 18: 357-364.
64. King J, Glick H, Mason T, Flamm E. Elective surgery for asymptomatic, unruptured intracranial aneurysms: a cost-effectiveness analysis. J Neurosurg 1995; 83:403-412.
65. Holloway R, Witter D, Lawton K, Libscomb J, Samsa G. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology 1996; 46:854-860.
66. Staff ME. Red book. Montvale, NJ: Medical Economics, 2000; 800.
67. Occupational outlook handbook: physicians and surgeons. U.S. Department of Labor Bureau of Labor Statistics Web site. Available at: http://stats.bls.gov/oco/ocos074.htm. Accessed June 16, 2003.
68. Lee J, Huber J, Stason W. Poststroke rehabilitation in older Americans: the Medicare experience. Med Care 1996; 34:811-825.
69. Weiner J, llston L, Hanley R. Sharing the burden: strategies for public and private long-term insurance. Washington, DC: Brookings Institute, 1993.
70. Sacco R, Shi T, Zamanillo M, Kargman D. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994; 44: 626-634.
71. Holloway R, Benesch C, Rahilly C, Courtright C. A systematic review of cost-effectiveness research of stroke evaluation and treatment. Stroke 1999; 30: 1340-1349.
72. Home page. U.S. Department of Labor Bureau of Labor Statistics. Available at: www.bls.gov. Accessed June 16, 2003.
73. Data warehouse home page. National Center for Health Statistics. Available at: www.cdc.gov/nchs/datawh/statab/unpubd/mortabs.htm. Accessed June 16, 2003.
74. Home page. U.S. Census Bureau. Available at: www.census.gov. Accessed June 16, 2003.
75. Sox H, Blatt M, Higgins M, Marton K. Medical decision making. Newton, Mass: Butterworth-Heinemann, 1988.
76. Hallan S, Asberg A, Indredavik B, Wideroe T. A decision analysis of thrombolytic therapy compared with standard therapy in acute ischaemic stroke. J Intern Med 1999; 246:549-559.
77. Brott T, Haley E, Levy D, Barsan W, Broderick J, Marler J. Thrombolytic therapy in acute ischemic stroke: strategies for early treatment of acute cerebral infarction. Berlin, Germany: Springer-Verlag, 1991; 197-203.
78. Brott T, Haley E, Levy D. Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23:632-640.
79. Kaste M, Palomaki H, Sarna S. Where and how should elderly stroke patients be treated? A randomized trial. Stroke 1995; 26:249-253.
80. Tengs T, Adams M, Pliskin J, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15:369-390.
81. Azimi N, Welch H. The effectiveness of cost-effectiveness analysis in containing costs. J Gen Intern Med 1998; 13:664-669.
82. Winkelmayer W, Weinstein M, Mittelman M, Glynn R, Pliskin J. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002; 22:417-430.
83. Morgenstern LB, Staub L, Chan W, et al. Improving delivery of acute stroke therapy: the TLL Temple Foundation Stroke Project. Stroke 2002; 33:160-166.